NCT02608697View on ClinicalTrials.gov

A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

June 30, 2016

Conditions
Hypercholesterolemia
Interventions
DRUG

CAT-2054

DRUG

Placebo

DRUG

Atorvastatin

Trial Locations (34)

10029

New York

14609

Rochester

23294

Richmond

29464

Mt. Pleasant

29485

Summerville

32792

Winter Park

33012

Hialeah

33026

Pembroke Pines

33458

Jupiter

34601

Brooksville

35662

Muscle Shoals

40213

Louisville

43213

Columbus

43302

Marion

44094

Willoughby Hills

44124

Lyndhurst

45005

Franklin

45219

Cincinnati

45227

Cincinnati

45246

Cincinnati

46260

Indianapolis

48098

Troy

60201

Evanston

60607

Chicago

66160

Kansas City

77036

Houston

77074

Houston

84058

Orem

89123

Las Vegas

90057

Los Angeles

90255

Huntington Park

90717

Lomita

98502

Olympia

04210

Auburn

Sponsors
All Listed Sponsors
lead

Catabasis Pharmaceuticals

INDUSTRY

NCT02608697 - A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia | Biotech Hunter | Biotech Hunter